Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Pathologic proof of adenocarcinoma of the prostate.~* Patients must belong to one of the following subsets:~* Prior local therapy~* Patients with Prostate Specific Antigen (PSA) recurrence following prostatectomy or radiation therapy who have no radiographic involvement. PSA doubling time ≤6 months.~* Nodal involvement only.~* Low volume bone disease: ≤3 metastases.~* Nodal involvement with associated bone involvement.~* High volume bone-visceral disease: Patients with \>3 metastatic bone sites or visceral metastases.~* No prior definitive local therapy~* Tumors felt to be unresectable, not candidates for radiation therapy, and PSA elevated with biopsy-proven disease.~* Metastatic disease at presentation.~* Patients may have started ADT within 3 months of study entry.~* No previous cytotoxic therapy is allowed, including systemic irradiation with strontium-89, samarium, or radium-223.~* Previous definitive radiotherapy to one metastatic site is acceptable, provided that unirradiated sites remain. At least 8 weeks must have elapsed since radiation therapy to the pelvis. Patients having limited irradiation of a metastatic site are eligible 4 weeks following radiation.~* Patients may have had previous exposure to ADT if it was given for ≤6 months to downstage the primary and provided that such therapy was completed at least 12 months prior to entry into this study with a return of serum testosterone to ≥200 ng/dL.~* Patients must be free of serious comorbidity and have a life expectancy of ≥3 years.~* Patients must have adequate physiologic reserves as evidenced by:~* Eastern Cooperative Oncology Group (ECOG) status of ≤2.~* Patients must have adequate bone marrow function: Platelets ≥100,000 cells/mm3, Hemoglobin ≥9.0 g/dL, and Absolute Neutrophil Count (ANC) ≥1,500 cells/mm3.~* Patients must have adequate renal function: creatinine ≤2 × upper limit of normal (ULN).~* Patients must have adequate liver function: Aspartate aminotransferase (AST) / Alanine transaminase (ALT) ≤2.5 × ULN; alkaline phosphatase \<2.5 × ULN, unless bone metastasis is present in the absence of liver metastasis; and bilirubin \< ULN or 1.5 mg/dl.~* No evidence of active ischemia on electrocardiogram (ECG) and documentation of ejection fraction (EF) ≥50%.~Exclusion criteria:~* Patients must not have a second malignancy unless there is confidence of previous curative therapy.~* Patients with a recent history of transient ischemic attack (TIA) (within 6 months), who are requiring regular antianginal therapy, or who are having claudication sufficient to limit activity are not eligible. Patients with a previous history of deep venous thrombosis or pulmonary embolism (within 12 months) are not eligible~* Patients must not have a serious intercurrent medical or psychiatric illness, including serious active infection.~* Patients must not have sensory neuropathy \> grade 1.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Definitive local therapy (Type: ACTIVE_COMPARATOR): 3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
- Nodal only/Low-volume bone (Type: ACTIVE_COMPARATOR): 4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
- High volume/no prior tx (Type: ACTIVE_COMPARATOR): 5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)

Based on this trial design, predict the completion outcome and termination type (if applicable).